サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1339241

糖尿病網膜症市場、シェア、市場規模、動向、産業分析レポート：タイプ別、管理法別、地域別、セグメント動向、2023年～2032年

Diabetic Retinopathy Market Share, Size, Trends, Industry Analysis Report, By Type (Proliferative DR, Non-proliferative DR); By Management (Intraocular Steroid Injection, Laser Surgery, Vitrectomy); By Region, And Segment Forecasts, 2023 - 2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 116 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
糖尿病網膜症市場、シェア、市場規模、動向、産業分析レポート：タイプ別、管理法別、地域別、セグメント動向、2023年～2032年
出版日: 2023年07月23日
発行: Polaris Market Research
ページ情報: 英文 116 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界の糖尿病網膜症市場規模は2032年までに152億3,000万米ドルに達する見込みです。このレポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

糖尿病の罹患率は大幅に上昇しており、世界の健康に大きな影響を与えています。国際糖尿病連合によると、糖尿病の罹患者数は2021年には約5億3700万人でした。この数字は、2030年には6億4,300万人に、2045年には驚異的な7億8,300万人にまで増加すると予測されています。糖尿病は、世界中で失明の主要な原因のひとつであると認識されています。

糖尿病による失明は、多くの場合、網膜の血管の漏れや破裂による損傷に起因します。視力低下の程度はさまざまで、永続的な障害から一時的な障害まで、病期によって異なります。調査によると、糖尿病に伴う視力障害のひとつである糖尿病網膜症の患者数は、2020年には約1億312万人になると推定されています。2045年には約1億6,050万人に増加すると予想されています。

高齢化社会は、糖尿病のような慢性疾患の有病率の上昇など、ヘルスケアの必要性という点で、独特の課題をもたらします。医療の進歩と平均寿命の改善により、65歳以上の高齢者数は大幅に増加すると予測されています。例えば、人口問題研究所による「米国の高齢化」レポートによると、米国の65歳以上の人口は2016年の約4,600万人から、2060年には9,800万人を超えると推定されています。

この人口動態の変化は、糖尿病網膜症を含む高齢化に伴う健康問題への取り組みの重要性を強調しています。ヘルスケアプロバイダーや市場のメーカーは、この拡大する人口の増大する需要に対応し、高齢者の糖尿病網膜症を管理し視力を維持するための効果的なソリューションを提供できるよう準備する必要があります。

COVID-19の大流行は、糖尿病網膜症の診断と治療を含め、世界中のヘルスケアシステムに大きな影響を与えました。パンデミック時に課された制約や制限により、糖尿病網膜症の早期発見と治療ガイドラインは大きな影響を受けた。糖尿病網膜症の一般的な治療法である硝子体内注射は、パンデミック中、2019年と比較して世界的に使用量が大幅に減少しました。減少率は様々であったが、約30％から100％以上でした。

糖尿病網膜症市場レポートハイライト

糖尿病患者数の増加により、2022年の世界市場シェアは非増殖性糖尿病網膜症セグメントが最も高い

高い有効性と優れた治療アルゴリズムにより、抗VEGF薬セグメントが最大シェアを占める

アジア太平洋地域は、膨大な未開拓人口と患者の意識の向上により、最も速いペースで成長

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の糖尿病網膜症市場に関する洞察

  • 糖尿病網膜症市場- 業界スナップショット
  • 糖尿病網膜症の市場力学
    • 促進要因と機会
      • 糖尿病の有病率の上昇と糖尿病による失明の増加
      • 糖尿病のケアと管理、および新製品の発売に対する意識の高まり
    • 抑制要因と課題
      • 高コスト
  • PESTLE分析
  • 糖尿病網膜症の業界動向
  • バリューチェーン分析
  • COVID-19感染症の影響分析

第5章 世界の糖尿病網膜症市場、タイプ別

  • 主な調査結果
  • イントロダクション
  • 増殖性糖尿病網膜症
  • 非増殖性糖尿病網膜症

第6章 世界の糖尿病網膜症市場、管理法別

  • 主な調査結果
  • イントロダクション
  • 抗VEGF
  • ステロイド眼内注射
  • レーザー手術
  • 硝子体手術

第7章 世界の糖尿病網膜症市場、地域別

  • 主な調査結果
  • イントロダクション
    • 糖尿病網膜症市場評価、地域別、2019～2032年
  • 糖尿病網膜症市場-北米
    • 北米：糖尿病網膜症市場、管理法別、2019～2032年
    • 北米：糖尿病網膜症市場、タイプ別、2019～2032年
    • 糖尿病網膜症市場-米国
    • 糖尿病網膜症市場- カナダ
  • 糖尿病網膜症市場- 欧州
    • 欧州：糖尿病網膜症市場、管理法別、2019～2032年
    • 欧州：糖尿病網膜症市場、タイプ別、2019～2032年
    • 糖尿病網膜症市場- 英国
    • 糖尿病網膜症市場- フランス
    • 糖尿病網膜症市場- ドイツ
    • 糖尿病網膜症市場- イタリア
    • 糖尿病網膜症市場- スペイン
    • 糖尿病網膜症市場- オランダ
    • 糖尿病網膜症市場- ロシア
  • 糖尿病網膜症市場- アジア太平洋
    • アジア太平洋：糖尿病網膜症市場、管理法別、2019～2032年
    • アジア太平洋：糖尿病網膜症市場、タイプ別、2019～2032年
    • 糖尿病網膜症市場- 中国
    • 糖尿病網膜症市場- インド
    • 糖尿病網膜症市場- マレーシア
    • 糖尿病網膜症市場- 日本
    • 糖尿病網膜症市場- インドネシア
    • 糖尿病網膜症市場- 韓国
  • 糖尿病網膜症市場-中東およびアフリカ
    • 中東およびアフリカ：糖尿病網膜症市場、管理法別、2019～2032年
    • 中東およびアフリカ：糖尿病網膜症市場、タイプ別、2019～2032年
    • 糖尿病網膜症市場- サウジアラビア
    • 糖尿病網膜症市場- アラブ首長国連邦
    • 糖尿病網膜症市場- イスラエル
    • 糖尿病網膜症市場- 南アフリカ
  • 糖尿病網膜症市場-ラテンアメリカ
    • ラテンアメリカ：糖尿病網膜症市場、管理法別、2019～2032年
    • ラテンアメリカ：糖尿病網膜症市場、タイプ別、2019～2032年
    • 糖尿病網膜症市場- メキシコ
    • 糖尿病網膜症市場- ブラジル
    • 糖尿病網膜症市場- アルゼンチン

第8章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第9章 企業プロファイル

  • Bayer
  • Allergan
  • Novartis
  • Oxurion
  • Sirnaomics
  • Genentech
  • Alimera Sciences
  • Ampio Pharmaceuticals
  • BCN Peptides
  • Kowa Company
図表

List of Tables

  • Table 1 Global Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 2 Global Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 3 Diabetic Retinopathy Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 4 North America: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 5 North America: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 6 U.S.: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 7 U.S.: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 8 Canada: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 9 Canada: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 10 Europe: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 11 Europe: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 12 UK: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 13 UK: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 14 France: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 15 France: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 16 Germany: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 17 Germany: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 18 Italy: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 19 Italy: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 20 Spain: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 21 Spain: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 22 Netherlands: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 23 Netherlands: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 24 Russia: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 25 Russia: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 26 Asia Pacific: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 27 Asia Pacific: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 28 China: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 29 China: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 30 India: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 31 India: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 32 Malaysia: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 33 Malaysia: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 34 Japan: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 35 Japan: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 36 Indonesia: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 37 Indonesia: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 38 South Korea: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 39 South Korea: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 40 Middle East & Africa: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 41 Middle East & Africa: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 42 Saudi Arabia: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 43 Saudi Arabia: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 44 UAE: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 45 UAE: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 46 Israel: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 47 Israel: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 48 South Africa: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 49 South Africa: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 50 Latin America: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 51 Latin America: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 52 Mexico: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 53 Mexico: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 54 Brazil: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 55 Brazil: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • Table 56 Argentina: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • Table 57 Argentina: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)

List of Figures

  • Figure 1 Global Diabetic Retinopathy Market, 2019-2032 (USD Billion)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by Management
  • Figure 7 Global Diabetic Retinopathy Market, by Management, 2022 & 2032 (USD Billion)
  • Figure 8 Market by Type
  • Figure 9 Global Diabetic Retinopathy Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 10 Diabetic Retinopathy Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 11 Strategic Analysis - Diabetic Retinopathy Market
目次
Product Code: PM3621

The global diabetic retinopathy market size is expected to reach USD 15.23 billion by 2032, according to a new study by Polaris Market Research. The report "Diabetic Retinopathy Market Share, Size, Trends, Industry Analysis Report, By Type (Proliferative DR, Non-proliferative DR); By Management (Intraocular Steroid Injection, Laser Surgery, Vitrectomy); By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The incidence of diabetes has been witnessing a significant surge, with a substantial impact on global health. According to the International Diabetes Federation, the number of individuals affected by diabetes was approximately 537 million in 2021. This figure is projected to increase to 643 million by 2030 and a staggering 783 million by 2045. Diabetes is recognized as one of the leading causes of blindness worldwide.

Blindness in individuals with diabetes is often attributed to the damage caused by leaking or ruptured blood vessels in the retina. The severity of vision loss can vary, ranging from permanent impairment to temporary disruptions depending on the stage of the disease. Research indicates that the number of cases of diabetic retinopathy, a specific form of vision impairment associated with diabetes, was estimated to be around 103.12 million in 2020. It is anticipated that the number of cases will escalate to approximately 160.5 million by 2045.

The aging population presents unique challenges in terms of healthcare needs, including a higher prevalence of chronic diseases like diabetes. With advancements in medical care and improved life expectancy, the number of individuals aged 65 years and over is projected to escalate substantially. For instance, the "Aging in the United States" report by the Population Reference Bureau indicates that the population of individuals aged 65 years and above in the U.S. is estimated to grow from approximately 46 million in 2016 to over 98 million by the year 2060.

This demographic shift underscores the importance of addressing health issues associated with aging, including diabetic retinopathy. Healthcare providers and manufacturers in the market must be prepared to meet the growing demands of this expanding population and provide effective solutions to manage diabetic retinopathy and preserve vision in older adults.

The COVID-19 pandemic had a substantial impact on healthcare systems worldwide, including the diagnosis and treatment of diabetic retinopathy. Due to the constraints and restrictions imposed during the pandemic, early detection and treatment guidelines for diabetic retinopathy were significantly affected. Intravitreal injections, which are a common treatment modality for diabetic retinopathy, experienced a significant decrease in usage globally during the pandemic compared to 2019. Reduction percentages varied but ranged from approximately 30% to over 100%.

Diabetic Retinopathy Market Report Highlights

Non-proliferative diabetic retinopathy segment accounted for highest global market share in 2022, due to rise in number of cases of diabetes

Anti-VEGF segment accounted largest share, due its high efficacy and better treatment algorithm

Asia Pacific region grown at the fastest rate, owing huge un-tapped population and better patient awareness

The global key market players include: Bayer, Allergan, Novartis, Oxurion, Sirnaomics, Genentech, Alimera Sciences, Ampio Pharmaceuticals, BCN Peptides, and Kowa Company.

Polaris Market Research has segmented the diabetic retinopathy market report based on type, management, and region:

Diabetic Retinopathy, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Proliferative Diabetic Retinopathy
  • Non-proliferative diabetic retinopathy

Diabetic Retinopathy, Management Outlook (Revenue - USD Billion, 2019 - 2032)

  • Anti-VEGF
  • Intraocular Steroid Injection
  • Laser Surgery
  • Vitrectomy

Diabetic Retinopathy, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Diabetic Retinopathy Market Insights

  • 4.1. Diabetic Retinopathy Market - Industry Snapshot
  • 4.2. Diabetic Retinopathy Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising prevalence of diabetes and increasing prevalence of blindness due to diabetes
      • 4.2.1.2. Growing awareness about diabetes care and management and new product launches
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Diabetic Retinopathy Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Diabetic Retinopathy Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Diabetic Retinopathy, by Type, 2019-2032 (USD Billion)
  • 5.3. Proliferating Diabetic retinopathy
    • 5.3.1. Global Diabetic Retinopathy Market, by Proliferating Diabetic retinopathy, by Region, 2019-2032 (USD Billion)
  • 5.4. Non proliferating Diabetic Retinopathy
    • 5.4.1. Global Diabetic Retinopathy Market, by Non proliferating Diabetic Retinopathy, by Region, 2019-2032 (USD Billion)

6. Global Diabetic Retinopathy Market, by Management

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
  • 6.3. Anti VEGF
    • 6.3.1. Global Diabetic Retinopathy Market, by Anti VEGF, by Region, 2019-2032 (USD Billion)
  • 6.4. Intraocular Steroid Injection
    • 6.4.1. Global Diabetic Retinopathy Market, by Intraocular Steroid Injection, by Region, 2019-2032 (USD Billion)
  • 6.4. Laser Surgery
    • 6.4.1. Global Diabetic Retinopathy Market, by Laser Surgery, by Region, 2019-2032 (USD Billion)
  • 6.5. Vitrectomy
    • 6.5.1. Global Diabetic Retinopathy Market, by Vitrectomy, by Region, 2019-2032 (USD Billion)

7. Global Diabetic Retinopathy Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Diabetic Retinopathy Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Diabetic Retinopathy Market - North America
    • 7.3.1. North America: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.3.2. North America: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
    • 7.3.3. Diabetic Retinopathy Market - U.S.
      • 7.3.3.1. U.S.: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
    • 7.3.4. Diabetic Retinopathy Market - Canada
      • 7.3.4.1. Canada: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.4. Diabetic Retinopathy Market - Europe
    • 7.4.1. Europe: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
    • 7.4.3. Diabetic Retinopathy Market - UK
      • 7.4.3.1. UK: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
    • 7.4.4. Diabetic Retinopathy Market - France
      • 7.4.4.1. France: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
    • 7.4.5. Diabetic Retinopathy Market - Germany
      • 7.4.5.1. Germany: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
    • 7.4.6. Diabetic Retinopathy Market - Italy
      • 7.4.6.1. Italy: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
    • 7.4.7. Diabetic Retinopathy Market - Spain
      • 7.4.7.1. Spain: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
    • 7.4.8. Diabetic Retinopathy Market - Netherlands
      • 7.4.8.1. Netherlands: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
    • 7.4.9. Diabetic Retinopathy Market - Russia
      • 7.4.9.1. Russia: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.5. Diabetic Retinopathy Market - Asia Pacific
    • 7.5.1. Asia Pacific: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
    • 7.5.3. Diabetic Retinopathy Market - China
      • 7.5.3.1. China: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
    • 7.5.4. Diabetic Retinopathy Market - India
      • 7.5.4.1. India: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
    • 7.5.5. Diabetic Retinopathy Market - Malaysia
      • 7.5.5.1. Malaysia: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
    • 7.5.6. Diabetic Retinopathy Market - Japan
      • 7.5.6.1. Japan: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
    • 7.5.7. Diabetic Retinopathy Market - Indonesia
      • 7.5.7.1. Indonesia: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
    • 7.5.8. Diabetic Retinopathy Market - South Korea
      • 7.5.8.1. South Korea: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.6. Diabetic Retinopathy Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
    • 7.6.3. Diabetic Retinopathy Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
    • 7.6.4. Diabetic Retinopathy Market - UAE
      • 7.6.4.1. UAE: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
    • 7.6.5. Diabetic Retinopathy Market - Israel
      • 7.6.5.1. Israel: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
    • 7.6.6. Diabetic Retinopathy Market - South Africa
      • 7.6.6.1. South Africa: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
  • 7.7. Diabetic Retinopathy Market - Latin America
    • 7.7.1. Latin America: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
    • 7.7.3. Diabetic Retinopathy Market - Mexico
      • 7.7.3.1. Mexico: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
    • 7.7.4. Diabetic Retinopathy Market - Brazil
      • 7.7.4.1. Brazil: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)
    • 7.7.5. Diabetic Retinopathy Market - Argentina
      • 7.7.5.1. Argentina: Diabetic Retinopathy Market, by Management, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Diabetic Retinopathy Market, by Type, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Bayer
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Allergan
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Novartis
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Oxurion
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Sirnaomics
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Genentech
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Alimera Sciences
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Ampio Pharmaceuticals
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. BCN Peptides
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Kowa Company
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development